Title: Affect of Neo-Adjuvant Chemotherapy in Management of Locally Advanced Breast Carcinoma
Authors: Naveen Konuku, Sahiti Thota, Thatha Rao Vepuri
DOI: https://dx.doi.org/10.18535/jmscr/v7i2.188
Abstract
Background: Introduction of neoadjuvent chemotherapy (NACT) has dramatically changed the management of locally advanced breast cancer (LABC). The neo-adjuvant chemotherapy (NACT) has become the initial standard treatment of locally advanced breast carcinoma cases followed by surgery, adjuvant chemotherapy, radiotherapy with or without hormonal therapy. Historically these cases with clinically locally advanced breast carcinoma were treated with radical surgery and/or radiation therapy (RT). However the management of LABC has dramatically transformed over past two decades {Bangladesh journal references 1-4}. Primary chemotherapy (CT) became an integral part of the multidisciplinary management of LABC, probably prolonging the disease free survival and overall survival and making breast conserving, less radical surgeries a possibility for these patients.{bangladesh journal}
Materials and Methods: All female patients with FNAC or core needle biopsy proven breast carcinoma attending general surgery department and specialty breast clinic at NRI general hospital, chinakakani, Guntur during two years of study.
Sample size of 30 / study period two years.
Results: Assessment of the clinical response was based on RECIST criteria with complete response in (CR) 4 cases (13.33%) partial response in (PR) 25 no (83.32%); minimal response or stable disease in (MR) 1 (3.33%); progressive disease in (PD) zero cases. Complete clinical response by clearance of axillary nodes is seen in 11(64.70%) of cases. No or partial response was seen in 6(35.29%). Assessment of the pathological response from the final surgical specimen showed
Complete response pCR 3 (9.99%)
Partial Response pPR 25(83.32%)
Stable diseases SD 2(6.66%)
Progressive diseases pPd 0 (0%)
Conclusion: Neoadjuvent chemotherapy is a reasonable alternative to upfront surgery in the management of LABC. Clinicopathological variables such as nodal status, response to chemotherapy, pathological tumor size and presence of ECE had significant impact on disease free survival.
Keywords: LABC, NACT, operability.
References
- Rahman MS, Akhter PS, Hasanuzzaman M, Rahman J, Bhattacharjee A, Rassell M et al. Dhaka; Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care center experience. Bangladesh Med J. 2016 Sept; 45(3);
- Hortobagyi GN, Blumenschein GR, Spanos W. Multimodal treatment of locoregionally advanced breast cancer. 1983; 51: 763-8.
- Davila E, Vogel CL. Management of locally advanced breast cancer (Stage III); a review. Int Adv Surg Oncol. 1984; 7 : 297-327.
- Hortobagyi GN, Ames FC, Buzdar AU. Management of stage III primary chemotherpy, surgery and radiation therapy. Cancer. 1988; 62: 2507-16.
- Hortobagyi GN, Buzdar AU. Locallt advanced breast cancer: A review including the MD Anderson experience. In: Ragaz J , Ariel IM, editors. High risk breast cancer therapy. Berlin: Springer- Verlag; 1991.pp. 416-23.
- Valero VV, Buzdar AU, Hortobagyi GN. Locally Advanced Breast Cancer. Oncologist. 1996;1:8–17. [PubMed]
- Fisher B, Brown A, Mamounas EL. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997;15:2483–93. [PubMed]
- Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: Findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer. 2002;95:681–95. [PubMed].